FibroBiologics wins European patent for enhancing fibroblast therapeutic activity
Bitget2026/09/29 12:32Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- FibroBiologics won a European patent for methods that condition fibroblasts with platelet-rich plasma, targeting stronger regenerative activity.
- Claims cover use of cytokines including FGF-alpha or FGF-beta, with additional protection for angiogenesis-related applications.
- Patent also targets spinal disc regeneration, reinforcing the company’s disc degeneration clinical program.
- Grant expands a portfolio of more than 270 issued or pending patents across fibroblast-based therapies.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290830PR_NEWS_USPR_____DA58792) on September 29, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
S&P/TSX Composite Index Higher Mid-Morning Tuesday as Information Technology Shares Shine
MT newswire•2026/09/29 14:35
Worthington Enterprises Insider Sold Shares Worth $2,567,545, According to a Recent SEC Filing
MT newswire•2026/09/29 14:30
